课题基金 / 基金详情

EFFICACY AND SAFETY OF ORAL RIDOGREL AS MAINTENANCE FOR ULCERATIVE COLITIS

EFFICACY AND SAFETY OF ORAL RIDOGREL AS MAINTENANCE FOR ULCERATIVE COLITIS
口服利多格雷维持治疗溃疡性结肠炎的功效和安全性
批准号：
6281701
负责人：
ALAN L. BUCHMAN
金额：
$1.36万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281701
关键词：
clinical research drug screening /evaluation endoscopy enzyme inhibitors gastrointestinal agents gastrointestinal disorder chemotherapy histology human subject human therapy evaluation oral administration remission /regression ulcerative colitis

项目摘要

项目成果

ALAN L. BUCHMAN的其他基金

相关文献

中文摘要
翻译
本研究将确定小剂量瑞格雷治疗慢性阻塞性肺疾病的疗效和安全性。 溃疡性结肠炎(UC)的维持缓解。这里的病人 多中心试验将实现UC的缓解 利格雷在活动期UC中的先前研究，或将处于缓解期 服用另一种药物的时间最长为6个月。他们将被随机化 口服利格雷，每日0.5，2.5或5.0毫克，持续一年。 患者将通过主观症状评估和内窥镜检查进行评估 和组织学参数。
英文摘要
This study will determine the efficacy and safety of low dose ridogrel for the maintenance of remission of ulcerative colitis (UC). Patients in this multicenter trial will have achieved remission of their UC while in a previous study of ridogrel in active UC, or will have been in remission for a maximum of 6 months on another medication. They will be randomized to receive oral ridogrel at 0.5, 2.5, or 5.0 mg daily for one year. Patients will be evaluated by subjective symptom evaluation and endoscopic and histologic parameters.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF HEPATIC STEATOSIS ASSOCIATED WITH TOTAL PARENTAL NUTRITION
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
SAFETY AND EFFICACY OF ISIS 2302 IN STEROID DEPENDENT CROHN'S DISEASE